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Background. Heme oxygenase (HO) products have a pro-
tective role in acute renal failure (ARF) that may be hemody-
namically mediated because the HO-derived carbon monoxide
(CO) is an important control system of arteriolar tone. The vas-
cular effects of HO may be caused directly through changes in
CO synthesis, and indirectly by alterations in nitric oxide (NO)
release. The present study evaluated in vivo the renal effects
of a heme oxygenase inhibitor, Co(III)Protoporphyrin (CoPP)
alone or in combination with the CO donor dimanganese de-
cacarbonyl (Mn2(CO)10).
Methods. All drugs were administered into the renal artery
of anesthetized rats. Changes in renal cortical nitric oxide con-
centration were measured in vivo electrochemically.
Results. The intrarenal administration of the CO donor
Mn2(CO)10 increased blood carboxyhemoglobin levels
(+74%), renal blood flow (+54%), glomerular filtration
(+38%), and urinary cGMP excretion (+128%). On the other
hand, the inhibition of renal HO with CoPP progressively
induced an ARF characterized by a drop in renal blood flow
(−77%), glomerular filtration (−93%), and urinary cGMP
excretion (−93%). These deleterious effects of HO inhibition
on renal function were nearly abolished by supplementing CO
with the coadministration of Mn2(CO)10 + CoPP, indicating
that they may be caused by inhibition of CO synthesis and the
resulting hemodynamic changes. In addition, CoPP lowered the
renal cortical NO concentration (−21%) and also decreased
the urinary excretion of nitrates/nitrites, while Mn2(CO)10
increased renal NO levels (+20%) and raised the excretion of
nitrates/nitrites, suggesting that changes in NO release may
contribute to the renal effects of the HO-CO system.
Conclusion. These results indicate that heme oxygenase–
derived CO plays a cardinal role in the control of renal hemo-
dynamics and glomerular filtration.
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Heme oxygenase (HO) is a mammalian enzyme
present in many tissues that catalyzes the oxidation of
heme to the biologically active molecules biliverdin, free
iron, and carbon monoxide (CO) [1]. Induction of HO
has been shown to be beneficial in a variety of models
of acute renal failure (ARF) [2–6]. On the other hand,
inhibition of HO or HO-1 gene ablation is deleterious
in certain models of acute renal injury [2–4, 7]. Despite
the attention centered on HO as a renal cytoprotective
system, little is known about the role of HO products in
controlling normal renal vascular and tubular function.
This may be relevant because renal hemodynamics are
thought to play a role in the development and recovery
from acute renal injury [8, 9]. Vasoconstrictors such as no-
radrenaline can cause renal failure [10], and vasodilators
(especially those cGMP-dependent) improve renal func-
tion in ARF [8–12]. The effects of HO products in ARF
may be hemodynamically mediated because HO appears
to be an important control system of vascular tone. HO in-
hibition reduces in vitro arteriolar diameter to near zero
values [13]; because this potent vasoconstrictor effect is
abolished by CO, a cGMP-dependent vasodilator [14, 15],
it seems reasonable to postulate that renal HO-derived
CO release may be influencing renal vascular function
and that part of the protective effects of HO on ARF
models may be caused by its renal vasodilatory actions.
At present, little is known about the role of HO-derived
CO in regulating renal function. The constitutive HO
(HO-2) is present in renal interlobar arteries, where CO
is released and attenuates the sensitivity to vasoconstric-
tors [16]. Recent reports [17–19] have shown that both
HO-1 and HO-2 are expressed in all regions of normal
kidneys, with levels increasing from the cortex to the inner
medulla. This may be of importance, because the infusion
of an HO inhibitor into the renal medulla reduces locally
blood flow and cGMP levels [19], and it is well known
that this region of the kidney is poorly oxygenated and
suffers the most severe damage in ischemic ARF [20, 21].
The distribution of HO isoforms has been studied in the
rat kidney [17], where HO-1 is mainly present in prox-
imal tubules and HO-2 in the thick ascending loop of
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Henle and preglomerular arterioles. In addition, it has
been found that CO may modulate sodium transport in
the thick ascending loop of Henle [18]. However, it is
unknown whether the HO system regulates normal renal
function in vivo or if it only has a role in pathophysiologic
conditions when HO-1 is induced. In this regard, it has
been reported that an HO inhibitor (zinc protoporphyrin
IX) has no significant effect on renal blood flow and ar-
terial pressure in normal rats unless HO is induced by
chronic hypoxia [22] or surgical stress [23]. Also, HO-1 is
induced by chronic administration of angiotensin II, and
the increased CO generation ameliorates the proteinuria
and the fall in glomerular filtration associated with this
form of hypertension [24, 25]. Therefore, the experimen-
tal evidence indicates that this paracrine system is present
in the kidney and may participate in the regulation of
renal vascular and tubular function in pathophysiologic
conditions, but no data are available concerning the phys-
iologic effects of CO or HO inhibition on renal function
in vivo.
It is becoming increasingly evident that the CO and
NO paracrine systems are intimately linked, but the func-
tional relevance of this interaction is poorly understood.
At a cellular level, both gases share the same second mes-
sengers, cGMP and cytochrome P450 products [14, 26–
28]. However, by metabolizing heme, HO depletes the
cell from other hemoproteins, such as cytochrome P450
[17, 29], nitric oxide synthase, or guanylyl cyclase [1], and
as a result of this, an inhibition of the biologic actions of
both CO and NO should be expected. In vitro experi-
ments using small renal arteries have shown that CO at
low concentrations (below 100 nmol/L) releases NO from
intracellular stores, while at high levels (up to 100 lmol/L)
CO inhibits NOS and lowers NO activity [30]. NO also
has a dual effect on the HO system—on one hand, NO
binds the heme group of the HO molecule, and inhibits
HO activity [31]; on the other hand NO induces HO-1,
therefore increasing CO generation [31–33]. Although
the physiologic renal effects of NO and CO should be
similar, at present the renal actions of CO and the possi-
ble interactions between both CO and NO in the control
of renal function are unknown.
The present study evaluated the effects of an intrarenal
infusion of a HO inhibitor, Co(III)Protoporphyrin
(CoPP), alone or in combination with the CO donor di-
manganese decacarbonyl (Mn2(CO)10), on renal func-
tion. To study in vivo the effects of CO on NO release,
the changes in renal cortical NO concentration during
Mn2(CO)10 or CoPP administration were also measured
electrochemically.
METHODS
Experiments were performed on 74 anesthetized male
Sprague-Dawley rats (−250 g of body weight) bred in
the Animal Care Facility at the University of Murcia.
All procedures were in accordance with the recommen-
dations of the Declaration of Helsinki and the guiding
principles in the care and use of animals approved by the
Council of the American Physiological Society. Rats were
anesthetized with an intramuscular injection of ketamine
(30 mg/kg, Rho`ne Merieux, Athens, GA, USA) and an
intraperitoneal injection of sodium thiopental (pentothal
50 mg/kg; Abbott, Madrid, Spain) and placed on a heated
table to maintain body temperature at 37◦C. Additional
doses of thiopental were given intravenously as required.
A tracheostomy was performed, allowing the animals to
breath spontaneously, and cannulas were placed in the
jugular vein for infusions, in the right femoral artery
for measurement of mean arterial pressure (MAP), and
in the left ureter for collection of urine. A heat-pulled
PE-10 catheter was inserted in the aorta and advanced
into the left renal artery for intrarenal infusions, as de-
scribed [28]. We have previously shown that intrarenal
infusions of vasodilators and vasoconstrictors can be per-
formed reproducibly with this technique [28]. Isotonic
NaCl solution was continuously infused at a rate of
1 mL/100g/h to maintain the patency of the catheter. An
electromagnetic flow probe (model 1401; Skalar Medi-
cal, Delft, The Netherlands) was placed around the left
renal artery for measurement of renal blood flow (RBF).
[3H]inulin (1 lCi/mL) was administered intravenously in
saline (1 mL/100g/h) for glomerular filtration rate (GFR)
measurements.
Measurement of renal cortical NO in vivo
These rats were surgically prepared as described above,
except that the left kidney was immobilized in a plastic
holder and maintained warm by a constant dripping of
saline at 37◦C, as it is done in renal micropuncture experi-
ments [34, 35]. Renal cortical NO concentration was mea-
sured by constant potential amperometry with an isolated
nitric oxide meter (ISO-NO MARK II; World Precision
Instruments, Sarasota, FL, USA), connected to a com-
puterized data acquisition system, as previously reported
[36]. The NO sensor was a carbon fiber 30 × 500 lm
covered with a gas permeable membrane (ISO-NOP30)
and polarized at +865 mV. This sensor is highly specific
for NO, and was calibrated as previously described [36,
37] by generating NO from S-nitro-N-acetylpenicillamine
in a solution containing copper. It has been shown that
this technique can be used to measure NO in the pres-
ence of different concentrations of CO with no interac-
tions [30]. A small portion of the renal capsule (<1 mm2)
was peeled off using microforceps and the microelectrode
was directly inserted into the renal cortex to a depth of
1.5 mm using a micromanipulator, with no visible bleed-
ing. The current difference between surface fluid and the
stable intrarenal reading was taken as the NO baseline
566 Arregui et al: Heme oxygenase and renal hemodynamics
signal, and the corresponding nanomolar concentration
was read off the calibration curve. The experiments be-
gan after an equilibration period of 60 minutes, when the
output current stabilized. NO activity was calculated by
averaging the output current during the last 15 minutes
of each experimental period, at a sampling rate of 1 Hz.
Quantitation of heme oxygenase activity
HO activity was measured as the rate of bilirubin
generation in rat kidney homogenates, as previously
described [38, 39]. Briefly, the rats were anesthetized,
the abdominal aorta was cannulated below and tied off
above the renal arteries, and the kidneys were washed by
flushing them with phosphate-buffered saline, removed,
quickly frozen in liquid nitrogen, and homogenized. The
kidney homogenates were centrifuged at 10,000g and
the supernatants were mixed with 2 mmol/L glucose 6-
phosphate, 1 U glucose 6-phosphate dehydrogenase, 25
lmol/L hemin, 0.25 mol/L sucrose, and 20 mmol/L Tris-
HCl buffer (pH 7.4). The reaction was started with 1
mmol/L NADPH, and the samples were incubated at
37◦C for 30 minutes. The formed bilirubin was extracted
with chloroform, and its concentration determined spec-
trophotometrically by measuring the difference spectrum
(464–530 nm) between test and reference samples, using
a bilirubin extinction coefficient of 40 mmol/L−1 · cm−1.
HO activity is reported as picomoles of bilirubin formed
per milligram of protein per hour.
Measurement of blood carboxyhemoglobin
concentration
The concentration of carboxyhemoglobin in blood
was determined spectrophotometrically as previously de-
scribed [40]. Blood samples were hemolyzed and diluted
in tris(hydroxymethyl)aminomethane (10 mmol/L), and
under N2 atmosphere, 2 mg/mL of sodium hydrosul-
fite were added to obtain a mixture of deoxygenated
hemoglobin (Hb) and carboxyhemoglobin (COHb).
The absorbance of this solution was measured at 420
and 432 nm, and the concentration of COHb calcu-
lated as: [COHb] = [[(A432.EHb420) − (A420.EHb432)]/
[(A420.(ECOHb432-EHb432)) − (A432.(ECOHb420-EHb420))]].
(A420/EHb420).
Experimental protocols
The experiments were designed to study the effects of
a carbon monoxide donor (Mn2(CO)10) as well as a HO
inhibitor (CoPP) on renal function and renal cortical NO
activity. All drugs were administered into the renal artery.
Group 1: Effects of CoPP and Sn protoporphyrin IX
(SnPP) on HO activity in renal homogenates (N = 5).
These experiments were performed to evaluate in vitro
the degree of HO inhibition produced by Co(III) pro-
toporphyrin IX (CoPP; Porphyrin Products, Logan, UT,
USA); the vascular effects of this compound were pre-
viously characterized in vitro by Kozma et al [13]. As a
comparison, the effects of a different HO inhibitor, SnPP,
were also determined. The effect of CoPP and SnPP (1
and 50 lmol/L, respectively) on HO activity were evalu-
ated in rat renal kidney homogenates as described above.
Group 2: Effects of the CO donor Mn2(CO)10 on blood
carboxyhemoglobin concentration and urinary cGMP ex-
cretion (N = 5). These experiments evaluated whether
dimanganese decacarbonyl, recently characterized as a
CO donor in vitro [41], is capable of releasing CO in
vivo and affecting renal function by stimulating guany-
lyl cyclase. Urine and blood samples were obtained
during a 15-minute control period. Then, an intrarenal
infusion of 80 nmol · kg−1 · min−1 of Mn2(CO)10 was
started (achieving a concentration of about 5 lmol/L in
renal arterial plasma at baseline renal blood flow) and
maintained for 1 hour, and urine and blood were again
sampled. Because Mn2(CO)10 only releases CO by pho-
todissociation, local CO generation was triggered in re-
nal tissue by exposing the kidney to a cold light source
[41]. This useful property of Mn2(CO)10 allows for the
evaluation of the renal effects of CO in the absence of
systemic changes. Blood carboxyhemoglobin levels were
determined as described above. Urinary cGMP excretion
was measured using a commercially available enzyme im-
munoassay (EIA) (Assay Designs).
Group 3: Effect of CoPP on plasma bilirubin concentra-
tion (N = 8). These experiments were performed to verify
whether CoPP inhibits HO in vivo. After control plasma
samples were obtained, two doses of CoPP (160 and
800 nmol · kg−1 · min−1) were consecutively infused dur-
ing 30 minutes each, and at the end of those two
experimental periods, plasma was again sampled. Plasma
bilirubin concentration was measured as described
below.
Group 4: Time course studies (N = 11). After surgery
and a 120-minute equilibration period, urine flow (UV),
sodium excretion (UNaV), RBF, GFR, and MAP
were measured at 30-minute intervals for 2 hours and
30 minutes.
Groups 5 and 6: renal effects of Co(III) Protoporphyrin
IX (n = 8) and Sn(IV) Protoporphyrin IX (N = 6). These
experiments were performed to evaluate in vivo the re-
nal effects of the HO inhibitors, CoPP and SnPP. Because
conventional solutions of porphyrins in NaOH 0.1M are
not very stable at physiologic pH, Co(III) and Sn(IV) pro-
toporphyrin IX were prepared as lysinate as Tenhunen et
al [42] previously synthesized iron protoporphyrin IX.
These derivatives of protoporphyrin IX are more stable
and soluble, preserving the properties of the porphyrins,
and can be administered intravascularly. CoPP was dis-
solved in phosphate-buffered saline (pH 7.4) on the day
of the experiment and infused intrarenally through an on-
line 0.25 lm Millipore filter (Madrid, Spain). UV, UNaV,
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GFR, and RBF were measured during two 15-minute
control periods. Then, five different doses of CoPP (16,
80, 160, 800, and 1600 nmol · kg−1 · min−1) were consec-
utively infused into the renal artery. These doses were
chosen because they would yield (at baseline RBF) con-
centrations in renal arterial plasma of ∼1, 5, 10, 50, and
100 lmol/L. Each dose was infused for 30 minutes, and
urine and plasma samples were collected during the last
15 minutes of the experimental period. Identical experi-
ments were performed with SnPP to compare the renal
vascular effects of CoPP with those of a different HO
inhibitor.
Group 7: Renal effects of the CO donor Mn2(CO)10
(N = 6). These experiments were performed to evalu-
ate the renal effects of dimanganese decacarbonyl. UV,
UNaV, GFR, and RBF were measured during a 15-
minute control period. Then, an intrarenal infusion of 80
nmol · kg−1 · min−1 of Mn2(CO)10 was started (achieving
a concentration of about 5 lmol/L in renal arterial plasma
at baseline renal blood flow) and maintained for 2 hours
and 30 minutes, and clearance periods were performed at
30-minute intervals until the end of the experiment. The
local CO release was produced in renal tissue by exposing
the kidney to a cold light source, as described above [41].
Group 8: Renal effects of Co(III) protoporphyrin IX in
rats given Mn2(CO)10 (N = 6). These experiments were
performed to evaluate the renal effects of HO inhibi-
tion in the presence of exogenously supplemented CO.
UV, UNaV, GFR, and RBF were measured during a
15-minute control period. Then, an intrarenal infusion
of 80 nmol · kg−1 · min−1 of Mn2(CO)10 was started and
maintained until the end of the experiment, and 30 min-
utes later, an additional clearance period was obtained.
Then, five different doses of CoPP (16, 80, 160, 800, and
1600 nmol · kg−1 · min−1) were consecutively infused into
the renal artery in the presence of Mn2(CO)10 (80 nmol ·
kg−1 · min−1). Each dose of CoPP was infused for 30 min-
utes, and urine and plasma samples were collected during
the last 15 minutes of the experimental period.
Group 9: Effects of CoPP and nitroarginine on renal
cortical NO concentration (N = 7). These experiments
examined the effects of CO synthesis blockade on renal
NO activity. To show that the output current of the car-
bon microelectrode is due to oxidation of tissue NO, the
effect of an intrarenal infusion nitroarginine methylester
(NAME) was also tested at the end of the experiment.
After the measurement of NO levels during a 15-minute
control period, two different doses of CoPP (160 and
800 nmol · kg−1 · min−1) were consecutively infused into
the renal artery for 30 minutes each, and NO activity was
redetermined. Finally, NAME (160 nmol · kg−1 · min−1)
was infused into the renal artery for 30 minutes, and the
resulting fall in renal tissue NO activity was recorded.
Group 10: Effects of Mn2(CO)10, CoPP and NAME on
renal cortical NO concentration (N = 7). These experi-
ments evaluated the effects of the CO donor Mn2(CO)10
alone or in combination with CoPP on renal cortical NO
activity. The effect of an intrarenal infusion of NAME was
also tested at the end of the experiment. After the deter-
mination of NO levels during a 15-minute control period,
Mn2(CO)10 (80 nmol · kg−1 · min−1) was infused into the
renal artery for 30 minutes, and NO activity was redeter-
mined. Then, CoPP (800 nmol · kg−1 · min−1) was coad-
ministered with the CO donor (80 nmol · kg−1 · min−1),
and 30 minutes later, NO was again measured. Finally,
NAME (160 nmol · kg−1 · min−1) was infused into the
renal artery for 30 minutes, and the resulting fall in renal
tissue NO activity was recorded.
Group 11: Effects of CoPP on renal blood flow, renal
cortical NO concentration, and renal temperature (N = 6).
These experiments were performed to correlate the ac-
tions of CoPP on renal hemodynamics and renal NO con-
centration. Because electrochemical NO measurements
can be affected by changes in temperature, the effects of
CoPP on renal temperature were also evaluated. These
experiments were performed as described above in pro-
tocol 7, except that an electromagnetic blood flow probe
was placed around the renal artery and a thermocouple
(diameter: 0.5 mm) was inserted into the renal cortex to
allow for the measurement of RBF and renal tempera-
ture, respectively, throughout the experiment. After the
measurement of basal NO levels, RBF, and temperature
during a 15-minute control period, two different doses
of CoPP (160 and 800 nmol · kg−1 · min−1) were con-
secutively infused into the renal artery for 30 minutes
each, and NO activity, RBF, and temperature were rede-
termined.
Group 12: Effect of NO synthesis inhibition on the renal
response to CoPP (N = 6). These experiments examined
the effect of blocking NO synthase with L-nitroarginine
methylester (L-NAME) on the renal response to in-
trarenal infusions of the HO inhibitor CoPP. These ex-
periments were similar to those described in protocol 5,
except that after a control period, the rats received and
intrarenal infusion of L-NAME (37 nmol · kg−1 min−1
for 30 minutes followed by 0.37 nmol · kg−1 · min−1
throughout the experiment) to suppress the endogenous
formation of NO [28]. After a 30-minute equilibration pe-
riod, urine and plasma samples were collected during a
15-minute clearance period. Then, the HO inhibitor
CoPP was infused intrarenally at doses of 80, 160, and
800 nmol · kg−1 · min−1, and urine and plasma samples
were again collected during the last 15-minute of three
additional 30-minute clearance periods.
Analytical methods
Urine volume was measured gravimetrically. 3H-inulin
concentrations in urine and plasma samples were deter-
mined by liquid scintillation spectrophotometry. GFR
was calculated as the ratio of urine to plasma inulin
568 Arregui et al: Heme oxygenase and renal hemodynamics
Table 1. Baseline measurements of MAP and renal function
MAP RBF GFR UV UNaV
mm Hg mL · min−1 · g−1 lL · min−1 · g−1 lL · min−1 · g−1 lEq · min−1 · g−1 FENa %
1 2 3 4 5 6 7 8 9 10 11 12
Group Saline Basal Saline Basal Saline Basal Saline Basal Saline Basal Saline Basal
4 (Time control) 111 ± 3 108 ± 3 7.9 ± 0.3 7.9 ± 0.3 1176 ± 92 1201 ± 95 33.0 ± 3.2 33.5 ± 3.2 6.1 ± 0.6 6.5 ± 0.6 3.8 ± 0.3 3.7 ± 0.2
5 (CoPP) 106 ± 5 105 ± 5 7.0 ± 0.7 6.9 ± 0.7 1133 ± 158 1168 ± 157 32.0 ± 5.5 30.9 ± 4.9 6.3 ± 1.1 6.4 ± 1.1 4.1 ± 0.6 3.9 ± 0.6
7 (Mn2(CO)10) 114 ± 4 114 ± 3 6.1 ± 0.2 6.0 ± 0.4 1254 ± 48 1372 ± 56 34.1 ± 7.0 29.9 ± 5.8 5.6 ± 1.1 4.9 ± 0.9 3.1 ± 0.5 2.8 ± 0.5
8 (Mn2(CO)10 110 ± 2 113 ± 1 6.5 ± 0.5 7.2 ± 0.3a 1179 ± 47 1277 ± 60 35.5 ± 5.3 36.7 ± 4.3 6.0 ± 0.6 5.9 ± 0.7 3.1 ± 0.5 2.7 ± 0.5
+ CoPP)
12 (L-NAME 118 ± 3 125 ± 4 6.1 ± 1.5 4.5 ± 1.5a 1260 ± 165 1287 ± 108 37.9 ± 6.3 18.5 ± 2.3a 6.9 ± 0.9 3.8 ± 0.3a 4.1 ± 0.6 2.1 ± 0.1a
+ CoPP
Abbreviations are: MAP, mean arterial pressure; RBF, renal blood flow; GFR, glomerular filtration rate; UV, urine flow; UNaV, sodium excretion; FENa, fractional
excretion of sodium. Values are mean ± SE. Numbers at left indicate group; numbers at top indicate column. All solutions were administered intrarenally. Before we
performed the dose-response studies, groups 4, 5, and 7 were infused with saline during the saline and basal periods. During the basal period of group 8, an infusion
of Mn2(CO)10 (80 nmol · kg−1 · min−1) was started. During the basal period of group 12, an infusion of L-NAME (37 nmol · kg−1 · min−1 for 30 minutes followed by
0.37 nmol · kg−1 · min−1 throughout the experiment) was started.
aIndicates significant difference from the saline period of the same group.
concentration times urine flow rate. The sodium concen-
tration of urine and plasma samples was determined with
a sodium-sensitive electrode. RBF, GFR, urine flow, and
Na+ excretion were factored by gram kidney weight. Uri-
nary nitrate+nitrite (NOx) excretion was measured us-
ing the Griess reaction after reduction of nitrate in the
samples by vanadium(III), as previously described [43].
Urinary cGMP was measured in samples preserved with
isobutylmethylxanthine (0.5 mmol/L) using a commer-
cially available EIA (Assay Designs) [28]. Plasma biliru-
bin concentration was measured spectrophotometrically
as the difference in absorbance between 475 and 514 nm,
because at these wavelengths the molar extinction coef-
ficient of CoPP is the same; therefore, the absorbance
difference is due to bilirubin.
Statistical methods
Data are presented as mean ± 1 SEM. The significance
of differences in the measured values within and between
groups was analyzed using an analysis of variance for re-
peated measures followed by Fisher least significant dif-
ference test. P < 0.05 (two-tailed test) was considered
statistically significant.
RESULTS
Baseline values of MAP, RBF, GFR, UV, UnaV, and
fractional excretion of sodium (FENa) for the rats in
groups 4–8 and 12 are presented in Table 1. Control
(saline) levels of blood pressure, RBF, UV, and UNaV
were similar in all groups. Intrarenal infusion of saline had
no effect on baseline renal function in groups 4, 5, and 7.
However, in group 8 the intrarenal infusion of Mn2(CO)10
increased RBF, and in group 12, the intrarenal infusion of
L-NAME reduced RBF and sodium and water excretion.
MAP remained unaltered throughout the experiment in
all groups. Hematocrit (−42%) was stable and similar in
all experimental groups.
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Fig. 1. Top: Effects of Co(III)Protoprophyrin IX (CoPP) and Sn Pro-
toporphyrin IX (SnPP) on heme oxygenase (HO) activity in renal ho-
mogenates. Middle: Effect of an intrarenal infusion of the CO donor
Mn2(CO)10 on blood carboxyhemoglobin concentration (Carboxy Hb)
and urinary cGMP excretion. ∗Indicates significant difference from con-
trol. Bottom: Effects of an intravenous infusion of CoPP on plasma
bilirubin concentration. ∗Indicates significant difference from control.
Effects of CoPP and SnPP on heme oxygenase activity.
Both porphyrins, CoPP and SnPP, had similar inhibitory
effects on HO activity in renal homogenates (Fig. 1, top).
CoPP reduced HO activity in a concentration-dependent
manner: the formation of bilirubin fell by 64% at 1 lmol/L
of CoPP, and by 85% at 50 lmol/L of CoPP.
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§Indicates a significant difference between the corresponding values in
the CoPP and the CoPP + Mn2(CO)10 groups; †indicates significant
difference from the corresponding value in the time control group.
Effects of Mn2(CO)10 on blood carboxyhemoglobin
concentration and urinary cGMP excretion. The in-
trarenal infusion of the CO donor increased both blood
carboxyhemoglobin levels (+74%) and the urinary ex-
cretion of cGMP (+128%, Fig. 1, middle).
Effects of CoPP on plasma bilirubin concentration. The
administration of CoPP (800 nmol · kg−1 · min−1) reduced
plasma bilirubin concentration to 42% of control (Fig. 1,
bottom).
Renal effects of CoPP. All renal parameters were re-
duced in a dose-dependent manner during the intrarenal
infusion of CoPP (Fig. 2). RBF and urine flow decreased
starting at the 160 nmol · kg−1 · min−1 dose, and fell dra-
matically after the highest dose of CoPP infused; RBF
dropped from a basal value of 6.9 ± 0.7 to 1.6 ± 0.6 mL ·
min−1 · g−1 during the administration of 1600 nmol · kg−1
· min−1 of CoPP, and urine flow fell from a baseline of
30.97 ± 4.9 to 4.4 ± 1.8 lL · min−1 · g−1 after the highest
dose of CoPP used. GFR decreased progressively from
the initial dose of 16 nmol · kg−1 · min−1, and the last dose
of CoPP induced an acute renal failure (from a basal of
1168 ± 157 to 71 ± 34 lL · min−1 · g−1). Sodium excre-
tion decreased significantly at the 160 nmol · kg−1 · min−1
dose, and fell near zero values at the dose of 160 nmol ·
kg−1 · min−1 of CoPP (from a basal value of 6.4 ± 1.1
to 0.78 ± 0.39 lEq · min−1 · g−1 during the last exper-
imental period). Fractional sodium excretion remained
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stable throughout the experiment until the last two doses
of CoPP, which produced a significant increase (from a
basal value of 3.9 ± 0.6 to 4.4 ± 0.7 and 7.6 ± 1.5%,
respectively). The administration of CoPP reduced the
urinary cGMP excretion (Fig. 3) from a basal value of
37.1 ± 6.8 to a minimum of 2.7 ± 1.7 pmol · min−1 · g−1.
Renal vascular effects of SnPP. The administration of
SnPP produced a renal vasoconstriction that was similar
to that observed during the infusion of CoPP. RBF fell
from a basal value of 6.4 ± 0.7 to 2.6 ± 0.4 mL · min−1 ·
g−1 during the administration of 1600 nmol · kg−1 · min−1
of SnPP (Fig. 4).
Renal effects of the CO donor Mn2(CO)10. The ad-
ministration of the CO donor had no effects on arterial
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pressure (basal value: 114.3 ± 3.2 mm Hg; 114.6 ± 3.3 mm
Hg at the end of the experiment). However, Mn2(CO)10
markedly increased RBF (from 6.0 ± 0.4 to 9.4 ± 0.7 mL ·
min−1 · g−1 (Fig. 2) and GFR (from 1372 ± 56 to a maxi-
mum of 1899 ± 279 lL · min−1 · g−1). These changes were
associated with augmented water and sodium excretion
(from 29.9 ± 5.8 to 82.4 ± 10.5 lL · min−1 · g−1 and from
4.9 ± 0.9 to 11.2 ± 1.9 lEq · min−1 · g−1, respectively).
The infusion of the CO donor also increased the urinary
excretion of cGMP (Fig. 3) from a basal of 43.2 ± 8.3 to
a maximum of 61.6 ± 8.2 pmol · min−1 · g−1).
Renal effects of CoPP in the presence of CO. The exoge-
nous supplementation of CO reduced the renal effects of
CoPP and prevented the development of an acute renal
failure during HO inhibition (Fig. 2). When compared
with the time-control group, RBF and GFR increased
during the first three experimental periods in rats given
CoPP + Mn2(CO)10, and they only decreased during the
last dose of the HO inhibitor (RBF: from a basal value of
7.2 ± 0.5 to 4.2 ± 1.3 mL · min−1 · g−1; GFR: from a basal
of 1277 ± 60 to 651 ± 151 lL · min−1 · g−1 respectively).
Sodium and water excretion increased during the first
four experimental periods, and they fell to values similar
to those seen in the time-control group at the end of the
experiment (Fig. 2). The exogenous CO supplementation
also attenuated the increase in fractional sodium excre-
tion produced by HO inhibition (7.6 ± 1.5 vs. 4.7 ± 1.3%
in rats given CoPP or CoPP + Mn2(CO)10, respectively).
Effects of CoPP and NAME on renal cortical NO con-
centration. The effects of HO and NO synthase inhibition
with CoPP and NAME, respectively, on renal cortical
NO concentration are presented in Figure 5 (top). The
intrarenal infusion of CoPP (160 nmol · kg−1 · min−1)
had no significant effects on renal cortical NO concentra-
tion. However, the subsequent administration of a higher
dose of CoPP (800 nmol · kg−1 · min−1) decreased NO re-
nal cortical concentration from a baseline of 450 ± 71 to
309 ± 82 nmol/L. Finally, the intrarenal administration of
NAME (160 nmol · kg−1 · min−1), reduced renal cortical
NO concentration further to 176 ± 87 nmol/L.
Effects of Mn2(CO)10, CoPP, and NAME on renal cor-
tical NO concentration. These data are presented in Fig-
ure 5 (middle). The intrarenal infusion of Mn2(CO)10 in-
creased the renal NO levels from a basal of 461 ± 56 to
552 ± 70 nmol/L. The addition of CoPP to the infusion
solution containing Mn2(CO)10 had no significant effects
on tissue NO levels. Finally, the infusion of NAME low-
ered renal NO concentration to 452 ± 58 nmol/L.
Effects of Mn2(CO)10 and CoPP on renal urinary ni-
trates/nitrites excretion. The excretion of NOx is pre-
sented in Figure 5 (bottom). The administration of the
HO inhibitor reduced urinary NOx excretion (17.1 ±
2.5 in time-control rats vs. 6.1 ± 3.3 nmol · min−1 ·
g−1 in rats given CoPP), while the intrarenal infusion
of the CO donor Mn2(CO)10 increased NOx excretion
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(to 27.5 ± 6.3 nmol · min−1 · g−1 at the end of the exper-
iment). In rats given Mn2(CO)10 + CoPP, the excretion
of NOx increased slightly with the dose of 160 nmol ·
kg−1 · min−1 of CoPP, and decreased thereafter to a
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minimum of 8.9 ± 2.2 nmol · kg−1 · min−1 at the end of the
experiment.
Correlation between the effects of CoPP on RBF and
renal NO concentration. Both RBF and renal [NO] fell
gradually during the intrarenal infusion of CoPP (160 and
800 nmol · kg−1 · min−1) (Fig. 6, top). Those changes were
well correlated (r = 0.96, P < 0.001) (Fig. 6, bottom).
Effects of CoPP on renal temperature. The intrarenal
infusion of CoPP (160 nmol · kg−1 · min−1) (Fig. 6, mid-
dle) had no effect on renal temperature. Only the higher
dose of CoPP (800 nmol · kg−1 · min−1) reduced renal
temperature from 36.4 ± 0.2 to 35.9 ± 0.3◦C. In in vitro
calibration experiments (data not shown) we found that
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basal period of the same group; §indicates a significant difference be-
tween the corresponding values in the CoPP and the L-NAME + CoPP
groups.
a decrease of 0.5◦C in temperature has no measurable
effect on the response of the NO electrodes.
Effects of NO synthesis inhibition on the renal response
to CoPP. The infusion of the 80 nmol · kg−1 · min−1 dose
of CoPP had no effect on RBF in rats pretreated with
L-NAME (Fig. 7), while this dose of CoPP produced sig-
nificant renal vasoconstriction in untreated rats. In ad-
dition, NO synthesis inhibition reduced the fall in GFR
and sodium and water excretion observed during the in-
trarenal administration of CoPP (80 and 160 nmol · kg−1 ·
min−1) (Fig. 7).
DISCUSSION
The present study evaluated the effects of an intrarenal
infusion of an HO inhibitor alone or with CO supple-
mentation on renal function. The administration of CoPP
induced a dose-dependent fall in renal blood flow and
glomerular filtration (starting at 160 nmol · kg−1 · min−1
of CoPP), reaching near zero values with the last dose
of CoPP used (1600 nmol · kg−1 · min−1). The induc-
tion of acute renal failure has also been observed during
the intrarenal infusion of other vasoconstrictors, such as
norepinephrine [10, 44]. This marked renal vasoconstric-
tion induced by CoPP is compatible with the previous
report that CoPP reduced in vitro the internal diameter
of pressurized gracilis muscle arterioles in a similar man-
ner, causing the near occlusion of the vascular lumen at
572 Arregui et al: Heme oxygenase and renal hemodynamics
a concentration of 100 lmol/L of CoPP [13]. These ob-
servations suggest that the vascular HO system is a key
physiologic controller of myogenic vascular tone. In ad-
dition, the renal vasoconstriction produced by the HO
inhibitor was associated with a parallel fall in the excre-
tion of sodium and water, as it can be observed in other
models of ARF [20, 45]. Our finding that intrarenal CoPP
induces an acute renal failure contrasts with those from
O’Donaughy and Walker [22], who reported no renal
vascular effect after the administration of 11 lmol/kg of
zinc protoporphyrin IX in conscious, chronically instru-
mented rats. This is likely due to the low concentrations
of the inhibitor achieved in renal arterial plasma, because
it has been recently reported that 40 lmol/kg of Sn meso-
porphyrin produces significant renal vasoconstriction in
anesthetized rats [46]. This point of view is also supported
by the observation in the present study that SnPP and
CoPP produced similar reductions in RBF, indicating that
the renal vascular effects of CoPP are likely due to HO
inhibition, and are not a side effect of the compound.
Overall, the data in the present study indicate that HO
is part of an important control system of renal vascular
function and glomerular filtration.
In the past, CoPP has been conventionally employed
in vivo as an inducer of HO activity in the kidney [47,
48]. However, in the present study this compound has
been used acutely as a HO inhibitor, based on the in-
hibitory effects on HO activity demonstrated in vitro
in renal homogenates, and also supported by the obser-
vation that CoPP lowers plasma bilirubin concentration
when administered in vivo. Nevertheless, the possibility
exists that the renal effects of CoPP may be caused by fac-
tors other than HO inhibition. This seems unlikely, how-
ever, because we have shown that the intrarenal infusion
of a different HO inhibitor, SnPP, produces similar renal
vasoconstriction as that seen during the administration
of CoPP.
The administration of a CO donor into the renal artery
also had important effects on renal function. Mn2(CO)10
produced significant renal vasodilation, and increased
glomerular filtration and urinary sodium and water excre-
tion. These effects are likely due to CO release, because
blood carboxyhemoglobin levels and urinary cGMP ex-
cretion increase during the infusion of Mn2(CO)10, indi-
cating that this is an effective CO donor capable of stim-
ulating guanylyl cyclase that can be used in vivo. These
data are consistent with previous reports showing in vitro
that CO solutions in the micromolar range increase the
diameter of renal afferent arterioles [30], and also other in
vivo studies demonstrating that when CO is applied top-
ically on pial vessels it acts on vascular smooth muscle
cells of the arterial wall and causes vasodilation [49]. The
CO donors seem to have the same vasodilatory effect,
because they produce vascular relaxation when applied
in vitro to precontracted aortic rings or to perfused coro-
nary vascular beds, and also reduce arterial pressure when
given intravenously in vivo [41]. Together, the data in the
present and previous studies indicate that CO influences
renal function in vivo.
The exogenous supplementation of CO markedly re-
duced the renal vascular and excretory effects of the HO
inhibitor and prevented the development of acute renal
failure, which is consistent with the idea that the effects
of CoPP are mainly due to suppression of endogenous
CO synthesis. This is in agreement with a previous in
vitro study [13], reporting that CO reduced gradually
the effects of Cr-mesoporphyrin, completely reversing
its vasoconstrictor effect at a concentration of CO of
100 lmol/L. The fact that the CO donor prevented the
drop in glomerular filtration and reduced the tubular
dysfunction induced by CoPP is also compatible with
previous studies showing that cGMP-dependent va-
sodilators ameliorate other models of ARF [9–12].
Overall, the data in the present study indicate that the
mechanisms inducing acute renal failure during HO inhi-
bition are of hemodynamic nature, and that the protective
effect of dimanganese decacarbonyl appears to be asso-
ciated with the maintenance of renal blood flow. From
this point of view, one may speculate that the protection
afforded by HO induction against acute renal failure [50]
may be related to improved renal hemodynamics during
the development of the syndrome. Therefore, the HO-
CO system appears to be a key controller of renal vascu-
lar function and glomerular filtration in physiologic and
pathophysiologic conditions.
Although the contribution of NO to the biologic ac-
tions of CO is still controversial, some data exist in-
dicating that CO may increase NO release in vitro in
microdissected renal resistance arteries [30]. Because it
has been shown that CO inhibits NO release from pure
NOS [30], probably by binding the iron in the heme group
of NOS [1], it has been postulated that CO acts by releas-
ing NO from an intracellular heme-bound pool. To test
this hypothesis in vivo, we measured amperometrically
NO levels in renal cortex during the intrarenal adminis-
tration of Mn2(CO)10 or CoPP. The CO donor increased
NO, while CoPP reduced NO cortical levels, which is com-
patible with a stimulatory effect of CO on NO release. As
another index of renal NO production, we also measured
the excretion of nitrates/nitrites as a part of the renal
function studies. Again, Mn2(CO)10 raised urinary NOx,
while CoPP reduced NOx excretion, in close agreement
with the electrochemical NO measurements. In addition,
the fact that acute pretreatment with L-NAME reduced
the renal effects of CoPP is compatible with the idea that
part of the renal actions of HO inhibition are related to
changes in NO release. This hypothesis is consistent with
previous studies showing that the vasodilatory effects of
CO involve NO as a permissive enabler [51]. However,
it has been recently reported that chronic NO synthesis
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blockade increases the renal vasoconstriction produced
by HO inhibition, because long-term NO suppression am-
plifies the prevailing neurohormonal constrictor mecha-
nisms [46]. Therefore, the available evidence indicates
that HO-derived CO is one of the components determin-
ing the basal equilibrium of neurohumoral factors influ-
encing renal vascular tone.
A possible methodologic problem might arise if the
renal vasoconstriction caused by the infusion of CoPP
reduced renal temperature, because this is known to af-
fect the response of NO electrodes. To avoid this, when
the kidney is placed into the plastic cup, a continuous
dripping of warm saline is performed to maintain renal
temperature, as it is done in conventional micropuncture
experiments [34, 35]. We have shown in the present study
that the 800 nmol · kg−1 · min−1 dose of CoPP lowers re-
nal temperature by only 0.5◦C, and that this small change
has no effect on the current produced by NO in the car-
bon fiber electrode, thus demonstrating that the changes
in NO measured are real and not due to an artifact.
CONCLUSION
The intrarenal infusion of an HO inhibitor induced an
acute renal failure that can be prevented by the exoge-
nous supplementation of carbon monoxide, indicating
that the endogenous HO-derived CO is a central con-
trol system of renal hemodynamics and glomerular filtra-
tion. The renal effects of CO seem to be partly mediated
through changes in NO release.
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